Board of Directors
Jeremy L. Curnock Cook
Chairman, Targeted Genetics
Executive Chairman
Bioscience Managers Limited
Jack L. Bowman
Former Group Chairman
Johnson & Johnson
Joseph M. Davie, Ph.D., M.D.
Former Senior VP Research
Biogen, Inc.
Roger L. Hawley
Chief Executive Officer
Zogenix, Inc.
Nelson L. Levy, Ph.D., M.D.
Chief Executive Officer
CoreTechs Corporation
H. Stewart Parker
President and CEO
Targeted Genetics Corporation
Michael S. Perry, D.V.M., Ph.D.
Venture Partner
Bay City Capital, and
Chief Development Officer
VIA Pharmaceuticals, Inc.
Management
H. Stewart Parker
President and CEO
Barrie J. Carter, Ph.D.
Executive Vice President
Chief Scientific Officer
David J. Poston
Vice President, Finance
Chief Financial Officer
Pervin Anklesaria, Ph.D.
Vice President, Therapeutic
Development
Richard W. Peluso, Ph.D.
Vice President, Process Sciences and Manufacturing
B.G. Susan Robinson
Vice President, Business Development
Haim Burstein, Ph.D.
Senior Director, Product Discovery
Kim Wieties Clary, Ph.D.
Senior Director, Intellectual Property
Alison E. Heald, M.D.
Senior Director, Clinical Affairs
Rae M. Saltzstein
Senior Director, Quality and
Regulatory Affairs
Stacie D. Byars
Director, Communications
Ralph W. Paul, Ph.D.
Director, Technology Evaluation
Ryan K. Takeya
Director, Manufacturing
Barbara A. Thorne, Ph.D.
Director, Process Development
|
Corporate Headquarters
Targeted Genetics Corporation
1100 Olive Way, Suite 100
Seattle, Washington 98101
Telephone 206.623.7612
www.targetedgenetics.com
Transfer Agent and Registrar
Mellon Investor Services
85 Challenger Road
Ridgefield Park, New Jersey 07660
Telephone 1.800.522.6645
Shareholder Inquiries
Inquiries regarding the company and its activities may be directed to the communications department at 206.521.7392. Communications concerning stock and
transfer requirements, lost certificates and changes of address should be directed to the transfer agent.
Legal Counsel
Orrick, Herrington & Sutcliffe LLP
Seattle, Washington
Independent Registered
Accounting Firm
Ernst & Young LLP
Seattle, Washington
Corporate Information
News releases and SEC filings are available on the Company’s website at: www.targetedgenetics.com.
Stock Listing
Targeted Genetics’ common stock is
traded on the Nasdaq Capital Market
under the symbol TGEN.
Common Stock
As of March 16, 2007, there are approximately 18,000 holders of Targeted Genetics’ common stock. Targeted Genetics has never paid dividends and the company does not anticipate
paying dividends in the foreseeable future.
Annual Meeting
The annual meeting of shareholders will be held at 9:00 a.m. on Thursday, May 17, 2007, at the Washington Athletic Club, 1325 Sixth Avenue, Seattle, Washington.
This Annual Report contains forward-looking statements. Forward-looking statements are based on the opinions and estimates of management
at the time the statements are made and are
subject to known and unknown risks and
uncertainties and inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the risks described under “Factors Affecting Our Operating Results, Our Business and Our Stock Price” in the Annual Report on Form 10-K for the year ended December 31, 2006, and in the filings made with the Securities and Exchange Commission from time to time. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. |
